Qiagen N.V. (NYSE:QGEN) Q2 2024 Earnings Call Transcript Q2 2024 Earnings Conference Call August 1, 2024 9:00 AM ET

Company Participants

John Gilardi - Investor Relations
Thierry Bernard - Chief Executive Officer and Managing Director
Roland Sackers - Chief Financial Officer and Managing Director

Conference Call Participants

Catherine Schulte - Baird
Michael Ryskin - Bank of America
Jack Meehan - Nephron Research
Dan Arias - Stifel
Odysseas Manesiotis - Berenberg Bank
Douglas Schenkel - Wolfe Research
Patrick Donnelly - Citi
Matthew Sykes - Goldman Sachs
Daniel Leonard - UBS
Falko Friedrichs - Deutsche Bank
Curtis Moiles - BNP Paribas
Daniel Brennan - TD Cowen

Operator

Ladies and gentlemen, thank you for standing by. I'm KD and I’ll be your conference operator. Welcome, and thank you for joining QIAGEN's Q2 2024 Earnings Conference Call Webcast. Please be advised that this call is being recorded at QIAGEN's request and will be made available on their Internet site. [Operator Instructions] At this time, I'd like to introduce your host, John Gilardi, Vice President of Corporate Communications and Investor Relations at QIAGEN. Please go ahead.

John Gilardi

Thank you, KD, and a welcome to all of you today who are joining in our call. We appreciate your interest in QIAGEN. Our speakers today are Thierry Bernard, our Chief Executive Officer, and Roland Sackers, our Chief Financial Officer. This call is being webcast live and will be archived on the investors section of our website at www.qiagen.com. You can also find a copy of the quarterly results press release and presentation on our website. We will begin with some remarks from Thierry and Roland, followed by a Q&A session.

Let’s go over the Safe Harbor statements. I’d like to remind everyone that we will be discussing statements. Actual results may differ materially from those projected in any statements that we make. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F on file with the SEC and also available on our website. Additionally, we will refer to certain financial measures not prepared, following generally accepted accounting principles or GAAP. All references to EPS refer to diluted EPS. You can also find a reconciliation to the most directly comparable GAAP measures in our press release in the presentation.

Now I would like to hand over to Thierry.

Thierry Bernard

Thank you, John. And hello and very good morning, good afternoon or good evening depending on where you are in the world and thank you once again for joining us. Our teams at QIAGEN executed well in the second quarter, delivering growth over quarter two of 2023 as well as sequential growth from the first quarter of 2024. In fact, our results position QIAGEN as among the fastest growing companies in the diversified tools sector. They also signal our conviction to accelerate our performance and achieve our updated outlook. Executing on our 2024 targets will put us on a good trajectory to achieve the new midterm targets we outlined at our Capital Markets Day that are underscored by our commitment to solid and profitable growth.